Amgen’s Imdelltra–Imfinzi combination cut lung cancer death risk by 58%
In a 563-patient trial of extensive-stage small cell lung cancer, Amgen’s Imdelltra combined with AstraZeneca’s Imfinzi reduced the risk of death by 58% compared with Imfinzi alone, according to results presented at the European Society for Medical Oncology meeting in Madrid. Median survival was 21.1 months with the combination and 12.7 months with Imfinzi alone; serious side effects were also more frequent with the combination.
Bottom line — Amgen reported that 20.9% of combination patients had serious side effects, versus 10.8% on Imfinzi alone.
Go deeper 5
-
Amgen said nearly 80% of patients on the combination were alive after one year, compared with 53% on Imfinzi alone.
-
Cytokine release syndrome occurred in 49.6% of patients receiving Imdelltra; one case was serious, with no related deaths, the company reported.
-
Side effects led to treatment discontinuation in 5.7% of combination patients and 5.8% of those on Imfinzi alone.
-
The Independent reported Imdelltra’s US list price at about €27,600 per cycle ($30,000), or more than €358,800 a year (over $390,000).
-
The Independent said the full trial results were published in the New England Journal of Medicine.